| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2008 | CA2300405C Use of cholinesterase inhibitors for treating attention deficit disorders |
| 01/22/2008 | CA2293589C Semisolid pharmaceutical formulation containing dexketoprofen trometamol |
| 01/22/2008 | CA2293553C Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase |
| 01/22/2008 | CA2283101C Quinoline leukotriene antagonists |
| 01/22/2008 | CA2281721C Phthalazines with angiogenesis inhibiting activity |
| 01/22/2008 | CA2272598C A process for the preparation of 4-(des-dimethylamino)-tetracyclines |
| 01/22/2008 | CA2222676C New pharmaceutical composition with anaesthetic effect |
| 01/22/2008 | CA2214321C Novel taxoids, preparation thereof and pharmaceutical compositions containing same |
| 01/22/2008 | CA2205136C Improved antiviral prodrugs of phosphonoacids |
| 01/22/2008 | CA2195419C Immunological activity of rhamnolipids |
| 01/21/2008 | CA2594196A1 Protease inhibiting polymer |
| 01/17/2008 | WO2008008981A1 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 01/17/2008 | WO2008008944A1 Pharmaceutical suspensions comprising phenylephrine and method of preparation |
| 01/17/2008 | WO2008008912A1 Antiviral agents |
| 01/17/2008 | WO2008008895A1 Gpr119 agonists for the treatment of diabetes and related disorders |
| 01/17/2008 | WO2008008884A2 Inhibition of beta-amyloid peptide aggregation |
| 01/17/2008 | WO2008008854A2 Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| 01/17/2008 | WO2008008852A2 Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| 01/17/2008 | WO2008008836A2 Composite solid phase polymerization catalyst |
| 01/17/2008 | WO2008008821A2 Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| 01/17/2008 | WO2008008802A2 Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
| 01/17/2008 | WO2008008770A2 6, 9-disubstituted purine derivatives and their use for treating skin |
| 01/17/2008 | WO2008008747A1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors |
| 01/17/2008 | WO2008008733A2 Nanoparticulate sorafenib formulations |
| 01/17/2008 | WO2008008720A2 Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance |
| 01/17/2008 | WO2008008704A2 Inhibitors of cyclic nucleotide synthesis and their use for therapy of various diseases |
| 01/17/2008 | WO2008008701A2 Substituted cyclopentane derivatives as therapeutic agents |
| 01/17/2008 | WO2008008700A2 Substituted cyclopentane derivatives as therapeutic agents |
| 01/17/2008 | WO2008008637A2 Antioxidant combinations for use in ruminant feed rations having a fat source |
| 01/17/2008 | WO2008008553A2 Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
| 01/17/2008 | WO2008008551A2 2-substituted proline bis-amide orexin receptor antagonists |
| 01/17/2008 | WO2008008549A2 Combination of an immunosuppressive agent and nonsteroidal anti -inflammatory drugs to treat neoplasia |
| 01/17/2008 | WO2008008539A2 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
| 01/17/2008 | WO2008008537A2 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent |
| 01/17/2008 | WO2008008518A1 Substituted diazepan orexin receptor antagonists |
| 01/17/2008 | WO2008008517A2 Bridged diazepan orexin receptor antagonists |
| 01/17/2008 | WO2008008513A2 Combination treatments |
| 01/17/2008 | WO2008008507A2 Methods of treatment of diabetes |
| 01/17/2008 | WO2008008494A2 Methods and compositions for treating mucosal inflammation |
| 01/17/2008 | WO2008008493A2 Alkyne-substituted pyridone compounds and methods of use |
| 01/17/2008 | WO2008008483A2 Dendrimer based compositions and methods of using the same |
| 01/17/2008 | WO2008008480A2 Nitroheteroaryl-containing rifamycin derivatives |
| 01/17/2008 | WO2008008474A2 Compositions and methods for the treatment of chronic pain conditions |
| 01/17/2008 | WO2008008468A2 Compositions and methods for fat reduction |
| 01/17/2008 | WO2008008453A1 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
| 01/17/2008 | WO2008008434A1 Controlled-release formulations |
| 01/17/2008 | WO2008008433A2 Substituted acylanilides and methods of use thereof |
| 01/17/2008 | WO2008008432A2 Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| 01/17/2008 | WO2008008398A2 Oxime compounds and the use thereof |
| 01/17/2008 | WO2008008394A1 Tizanidine succinate salt forms and methods of making and using the same |
| 01/17/2008 | WO2008008380A1 Combination therapy for addiction disorders |
| 01/17/2008 | WO2008008375A2 Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
| 01/17/2008 | WO2008008364A2 Enhanced stability phenylephrine liquid compositions |
| 01/17/2008 | WO2008008359A2 Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor |
| 01/17/2008 | WO2008008327A2 Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| 01/17/2008 | WO2008008273A1 Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide |
| 01/17/2008 | WO2008008234A1 2-amino-5-substituted pyrimidine inhibitors |
| 01/17/2008 | WO2008008215A2 Method for enhancing pdt efficacy using a tyrosine kinase inhibitor |
| 01/17/2008 | WO2008008161A2 Methods and composition for treating a material |
| 01/17/2008 | WO2008008113A1 Improved antibacterial antisense oligonucleotide and method |
| 01/17/2008 | WO2008008059A1 Anti-cancer agents ans uses thereof |
| 01/17/2008 | WO2008008057A1 Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof |
| 01/17/2008 | WO2008008033A1 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia |
| 01/17/2008 | WO2008008022A1 Isoindoline derivatives for the treatment of arrhythmias |
| 01/17/2008 | WO2008008020A1 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
| 01/17/2008 | WO2008007999A1 Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) |
| 01/17/2008 | WO2008007991A1 A method for the production of fentanyl - based anesthetics for their oral transmucosal administration in a candy -l ike dosage form |
| 01/17/2008 | WO2008007979A1 (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| 01/17/2008 | WO2008007921A1 Paroxetine hydrochloride-containing sustained-release tablet having reduced dissolution variation |
| 01/17/2008 | WO2008007835A1 2,4-quinazoline derivatives having activity to t-type calcium channel and preparation method thereof |
| 01/17/2008 | WO2008007780A1 Pentadienamide derivative |
| 01/17/2008 | WO2008007766A1 Crystal of benzoxadiazole derivative |
| 01/17/2008 | WO2008007728A1 Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient |
| 01/17/2008 | WO2008007691A1 Salt of morpholine compound |
| 01/17/2008 | WO2008007664A1 Bicyclic heterocyclic compound and use thereof |
| 01/17/2008 | WO2008007661A1 Tricyclic heterocyclic compound and use thereof |
| 01/17/2008 | WO2008007654A1 Prophylactic and/or therapeutic agent for aneurysm |
| 01/17/2008 | WO2008007554A1 Adhesive preparation |
| 01/17/2008 | WO2008007426A1 Analgesic agent |
| 01/17/2008 | WO2008007415A1 Inclusion coenzyme q10 and method of producing inclusion coenzyme q10 |
| 01/17/2008 | WO2008007381A2 Container partially covered by chemoluminescent glow apparatus |
| 01/17/2008 | WO2008007367A1 Combination methods of treating cancer |
| 01/17/2008 | WO2008007211A1 Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| 01/17/2008 | WO2008007210A2 Nitrogenous n-substituted 4-spiro-heterocyclic 2, 2 -dimethylchromane derivatives |
| 01/17/2008 | WO2008007182A2 Topical pharmaceutical compositions of mupirocin or pharmaceutically acceptable salts or esters thereof |
| 01/17/2008 | WO2008007152A2 Preparation of pharmaceutical formulations |
| 01/17/2008 | WO2008007151A2 Processes for preparing pharmaceutical compositions |
| 01/17/2008 | WO2008007150A1 Preparation of pharmaceutical compositions |
| 01/17/2008 | WO2008007149A2 New medical use of triazine derivatives |
| 01/17/2008 | WO2008007131A2 Treatment for demyelinating disease |
| 01/17/2008 | WO2008007130A1 Furo [3,2-b] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 01/17/2008 | WO2008007127A1 Furo [3,2-b] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 01/17/2008 | WO2008007123A2 Pharmaceutical compounds |
| 01/17/2008 | WO2008007117A1 Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate |
| 01/17/2008 | WO2008007114A1 Tetrahydrofuro [3, 2 -b] pyrr0l-3-ones as cathepsin k inhibitors |
| 01/17/2008 | WO2008007113A2 Pharmaceutical combinations |
| 01/17/2008 | WO2008007112A1 Tetrahydrofuro [3, 2-b] pyrr0l-3-ones as cathepsin k inhibitors |
| 01/17/2008 | WO2008007109A1 Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors |
| 01/17/2008 | WO2008007107A1 Tetrahydrofuro (3, 2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| 01/17/2008 | WO2008007104A1 Use of tylvalosin as antiviral agent |